利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.019 秒)

    NOVEL BICYCLIC COMPOUNDS
    1.
    发明申请
    NOVEL BICYCLIC COMPOUNDS 有权
    新型双环化合物

    公开(公告)号：US20130253029A1

    公开(公告)日：2013-09-26

    申请号：US13876757

    申请日：2011-09-27

    申请人： Rajesh Jain ,  Sanjay Trehan ,  Jagattaran Das ,  Nishan Singh ,  Sudhir Kumar Sharma

    发明人： Rajesh Jain ,  Sanjay Trehan ,  Jagattaran Das ,  Nishan Singh ,  Sudhir Kumar Sharma

    IPC分类号： C07D209/52 ,  A61K45/06 ,  A61K31/403

    CPC分类号： C07D209/52 ,  A61K31/403 ,  A61K45/06

    摘要： The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention further provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more disorders of the central and/or peripheral nervous system, preferably by modulating neurological and/or psychiatric targets (GPCR and/or non-GPCR).

    摘要翻译： 本发明涉及式I的新化合物，其药学上可接受的衍生物，互变异构形式，异构体，多晶型物，前药，代谢物，盐或溶剂化物。 本发明还涉及合成式I的新化合物，其药学上可接受的衍生物，互变异构形式，异构体，多晶型物，前药，代谢物，盐或溶剂合物的方法。 本发明还提供包含式I化合物的药物组合物和治疗或预防中枢和/或周围神经系统的一种或多种病症的方法，优选通过调节神经和/或精神病学靶标（GPCR和/或非GPCR） 。

    Bicyclic compounds
    2.
    发明授权
    Bicyclic compounds 有权
    双环化合物

    公开(公告)号：US09133116B2

    公开(公告)日：2015-09-15

    申请号：US13876757

    申请日：2011-09-27

    申请人： Rajesh Jain ,  Sanjay Trehan ,  Jagattaran Das ,  Nishan Singh ,  Sudhir Kumar Sharma

    发明人： Rajesh Jain ,  Sanjay Trehan ,  Jagattaran Das ,  Nishan Singh ,  Sudhir Kumar Sharma

    IPC分类号： C07D209/52 ,  A61K31/403 ,  A61K45/06

    CPC分类号： C07D209/52 ,  A61K31/403 ,  A61K45/06

    摘要： The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention further provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more disorders of the central and/or peripheral nervous system, preferably by modulating neurological and/or psychiatric targets (GPCR and/or non-GPCR).

    摘要翻译： 本发明涉及式I的新化合物，其药学上可接受的衍生物，互变异构形式，异构体，多晶型物，前药，代谢物，盐或溶剂化物。 本发明还涉及合成式I的新化合物，其药学上可接受的衍生物，互变异构形式，异构体，多晶型物，前药，代谢物，盐或溶剂合物的方法。 本发明还提供包含式I化合物的药物组合物和治疗或预防中枢和/或周围神经系统的一种或多种病症的方法，优选通过调节神经和/或精神病学靶标（GPCR和/或非GPCR） 。

    SGLT inhibitors
    3.
    发明授权
    SGLT inhibitors 有权
    SGLT抑制剂

    公开(公告)号：US09018249B2

    公开(公告)日：2015-04-28

    申请号：US14344628

    申请日：2012-09-12

    申请人： Rajesh Jain ,  Sanjay Trehan ,  Jagattaran Das ,  Gurmeet Kaur Nanda ,  Sastry V. R. S. Thungathurthi ,  Nishan Singh ,  Sudhir Kumar Sharma

    发明人： Rajesh Jain ,  Sanjay Trehan ,  Jagattaran Das ,  Gurmeet Kaur Nanda ,  Sastry V. R. S. Thungathurthi ,  Nishan Singh ,  Sudhir Kumar Sharma

    IPC分类号： A61K31/352 ,  C07D311/00 ,  C07D309/10 ,  C07D493/08

    CPC分类号： C07D309/10 ,  C07D493/08 ,  C07H7/04

    摘要： The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).

    摘要翻译： 本发明涉及式I的新化合物，其药学上可接受的衍生物，互变异构形式，异构体，多晶型物，前药，代谢物，盐或溶剂化物。 本发明还涉及合成式I的新化合物，其药学上可接受的衍生物，互变异构形式，异构体，多晶型物，前药，代谢物，盐或溶剂合物的方法。 本发明还提供包含式I的新化合物和治疗或预防一种或多种可通过抑制葡萄糖转运蛋白-2（SGLT-2）调节或归一化的病症或疾病的药物组合物。

    NOVEL SGLT INHIBITORS
    5.
    发明申请
    NOVEL SGLT INHIBITORS 有权
    新型SGLT抑制剂

    公开(公告)号：US20140378540A1

    公开(公告)日：2014-12-25

    申请号：US14344628

    申请日：2012-09-12

    申请人： Rajesh Jain ,  Sanjay Trehan ,  Jagattaran Das ,  Gurmeet Kaur Nanda ,  Sastry V. R. S Thungathurthi ,  Nishan Singh ,  Sudhir Kumar Sharma

    发明人： Rajesh Jain ,  Sanjay Trehan ,  Jagattaran Das ,  Gurmeet Kaur Nanda ,  Sastry V. R. S Thungathurthi ,  Nishan Singh ,  Sudhir Kumar Sharma

    IPC分类号： C07D309/10 ,  C07D493/08

    CPC分类号： C07D309/10 ,  C07D493/08 ,  C07H7/04

    摘要： The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).

    摘要翻译： 本发明涉及式I的新化合物，其药学上可接受的衍生物，互变异构形式，异构体，多晶型物，前药，代谢物，盐或溶剂化物。 本发明还涉及合成式I的新化合物，其药学上可接受的衍生物，互变异构形式，异构体，多晶型物，前药，代谢物，盐或溶剂合物的方法。 本发明还提供包含式I的新化合物和治疗或预防一种或多种可通过抑制葡萄糖转运蛋白-2（SGLT-2）调节或归一化的病症或疾病的药物组合物。

    Heterocyclic compounds
    9.
    发明授权
    Heterocyclic compounds 有权
    杂环化合物

    公开(公告)号：US08455479B2

    公开(公告)日：2013-06-04

    申请号：US12863016

    申请日：2009-01-23

    申请人： Rajesh Jain ,  Sanjay Trehan ,  Jagattaran Das ,  Nishan Singh ,  Gurmeet Kaur Nanda ,  Sitaram Kumar Magadi ,  Sudhir Kumar Sharma

    发明人： Rajesh Jain ,  Sanjay Trehan ,  Jagattaran Das ,  Nishan Singh ,  Gurmeet Kaur Nanda ,  Sitaram Kumar Magadi ,  Sudhir Kumar Sharma

    IPC分类号： C07D243/14 ,  C07D403/06 ,  C07D413/12 ,  C07D487/04 ,  A61K31/551 ,  A61P3/10

    CPC分类号： C07D243/14 ,  C07D403/06 ,  C07D413/12 ,  C07D487/04

    摘要： The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more conditions that may be regulated or normalized via inhibition of dipeptidyl peptidase IV (DPP-IV).

    摘要翻译： 本发明涉及式I的新化合物，其药学上可接受的衍生物，互变异构体，立体异构体，包括R和S异构体，多晶型物，前药，代谢物，盐或溶剂化物。 本发明还涉及合成式I的新化合物，其药学上可接受的衍生物，互变异构形式，立体异构体，多晶型物，前药，代谢物，盐或溶剂合物的方法。 本发明还提供包含式I化合物的药物组合物以及通过抑制二肽基肽酶IV（DPP-IV）来治疗或预防可被调节或归一化的一种或多种病症的方法。